FIGURE 1 Results and Discussion Oral Semaglutide Has Great Potential for the Prevention of Retinal Neurodegeneration There is a demonstrated neuroprotective effect of GLP-1R agonists in both the retina and brain in preclinical studies of ocular hypertension, diabetic retinopathy, Alzheimers disease, Parkinsons disease, stroke, neuropathy, and several other neurodegenerative diseases (Kastin et al., 2002
These symptoms typically emerge during dose escalation and often diminish over several weeks as physiological adaptation occurs
They mimic a natural hormone your body already produces one that helps control appetite, blood sugar, and digestion
Immunoregulatory drugs (IL-2, denileukin diftitox, thalidomide and lenalidomide, IFN-, alemtuzumab) and immune checkpoint inhibitors (anti-CTLA4 and anti-PD-1 monoclonal antibodies) mainly promote thyroid autoimmunity
Real-world signals
Tirzepatide behaves differently from the single-target GLP-1 agonists, and that difference is worth understanding before you pair it with any telehealth program
